Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

Or-Yam Revach,Angelina M. Cicerchia,Ofir Shorer,Boryana Petrova,Seth Anderson,Joshua Park,Lee Chen,Arnav Mehta,Samuel J. Wright,Niamh McNamee,Aya Tal-Mason,Giulia Cattaneo,Payal Tiwari,Hongyan Xie,Johanna M. Sweere,Li-Chun Cheng,Natalia Sigal,Elizabeth Enrico,Marisa Miljkovic,Shane A. Evans,Ngan Nguyen,Mark E. Whidden,Ramji Srinivasan,Matthew H. Spitzer,Yi Sun,Tatyana Sharova,Aleigha R. Lawless,William A. Michaud,Martin Q. Rasmussen,Jacy Fang,Claire A. Palin,Feng Chen,Xinhui Wang,Cristina R. Ferrone,Donald P. Lawrence,Ryan J. Sullivan,David Liu,Uma M. Sachdeva,Debattama R. Sen,Keith T. Flaherty,Robert T. Manguso,Lloyd Bod,Manolis Kellis,Genevieve M. Boland,Keren Yizhak,Jiekun Yang,Naama Kanarek,Moshe Sade-Feldman,Nir Hacohen,Russell W. Jenkins

DOI: https://doi.org/10.1101/2024.02.12.579184

2024-03-26

Abstract:A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma . T cell exhaustion, resulting from chronic antigen exposure in the tumour microenvironment, is a major driver of ICB resistance . Here, we show that CD38, an ecto-enzyme involved in nicotinamide adenine dinucleotide (NAD ) catabolism, is highly expressed in exhausted CD8 T cells in melanoma and is associated with ICB resistance. Tumour-derived CD38 CD8 T cells are dysfunctional, characterised by impaired proliferative capacity, effector function, and dysregulated mitochondrial bioenergetics. Genetic and pharmacological blockade of CD38 in murine and patient-derived organotypic tumour models (MDOTS/PDOTS) enhanced tumour immunity and overcame ICB resistance. Mechanistically, disrupting CD38 activity in T cells restored cellular NAD pools, improved mitochondrial function, increased proliferation, augmented effector function, and restored ICB sensitivity. Taken together, these data demonstrate a role for the CD38-NAD axis in promoting T cell exhaustion and ICB resistance, and establish the efficacy of CD38 directed therapeutic strategies to overcome ICB resistance using clinically relevant, patient-derived 3D tumour models.

Cancer Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the issue of resistance to immune checkpoint blockade (ICB) treatment in cancer immunotherapy. Specifically, the study focused on the relationship between the high expression of CD38 (an ectoenzyme involved in nicotinamide adenine dinucleotide NAD+ metabolism) in exhausted CD8+ T cells and ICB resistance. The researchers found that CD38 is highly expressed in exhausted CD8+ T cells, and this expression is closely related to the resistance to ICB treatment. Inhibiting the activity of CD38 by genetic and pharmacological means can restore the function of these T cells, thereby improving the efficacy of ICB treatment. ### Research Background - **Challenges of ICB Treatment**: Although ICB treatment has achieved significant efficacy in some cancer patients, approximately 50% of metastatic melanoma patients are still resistant to ICB treatment. T - cell exhaustion is one of the main factors leading to ICB resistance. - **The Role of CD38**: CD38 is highly expressed in exhausted CD8+ T cells, and these cells exhibit decreased proliferative capacity, weakened effector function, and mitochondrial bioenergetic dysregulation. ### Research Objectives - **Explore the Relationship between CD38 and ICB Resistance**: The researchers aimed to investigate whether the high expression of CD38 in exhausted CD8+ T cells is related to ICB resistance. - **Verify the Potential of CD38 as a Therapeutic Target**: By inhibiting the activity of CD38, the researchers hope to restore the function of T cells, thereby overcoming ICB resistance. ### Main Findings - **The Association between CD38 and ICB Resistance**: The researchers found that CD38 is highly expressed in exhausted CD8+ T cells, and this expression is closely related to ICB resistance. - **CD38 Inhibition Restores T - cell Function**: By inhibiting the activity of CD38 through genetic and pharmacological means, the NAD+ level of T cells can be restored, mitochondrial function can be improved, proliferative capacity and effector function can be enhanced, and thus the sensitivity to ICB treatment can be restored. - **Pre - clinical Model Validation**: In mouse and patient - derived organoid tumor models (PDOTS), the combination of CD38 inhibitors and ICB significantly improved the anti - tumor effect, especially in melanoma patients resistant to ICB. ### Conclusions - **The Role of the CD38 - NAD+ Axis in T - cell Exhaustion and ICB Resistance**: The research results indicate that the CD38 - NAD+ axis plays a crucial role in promoting T - cell exhaustion and ICB resistance. - **CD38 as a Potential Therapeutic Target**: By targeting CD38, ICB resistance can be effectively overcome, providing a theoretical basis for the development of new treatment strategies. In summary, through systematic research, this paper reveals the important role of CD38 in T - cell exhaustion and ICB resistance, and proposes a new strategy of inhibiting CD38 to restore T - cell function and improve the efficacy of ICB treatment. This finding provides an important scientific basis for the further development of cancer immunotherapy.

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

CD38-NAD(+) Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response

CD38–RyR2 axis–mediated signaling impedes CD8+ T cell response to anti-PD1 therapy in cancer

A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

OA 13.01 CD38-Mediated Immunometabolic Suppression As a Mechanism of Resistance to PD-1/PD-L1 Axis Blockade

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Abstract 567: CD38 Blockade Overcomes the Immune Resistance to Anti-Pd-l1 Therapy by Boosting CD8 T Cell Response

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment

Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism

Functional Assessment of the Cell-Autonomous Role of NADase CD38 in Regulating CD8+ T Cell Exhaustion.

P853 Single cell transcriptome analysis identifies unique features in circulating CD8+ T cells that can predict immunotherapy response in melanoma patients

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer

Targeting TNFR2 to overcome acquired adaptive resistance to immune checkpoint blockade

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.

Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy

Enhancing CD8+ T Cell Fatty Acid Catabolism Within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.